PROM1 and glioblastoma: To determine the mechanism by which NXD30001 achieves its antitumor and radio-sensitizing effects on GSCs, we assessed the levels of known Hsp90 client proteins involved in GBM pathology when treated with 17-AAG or NXD30001 in T4105 CD133+ cells and treated with NXD30001 ± 3 Gy radiation in T4302 CD133+ cells.